Quarterly Result29 Jul 2025, 12:43 pm
Strides Pharma Science Ltd Reports Q1 FY 2026 with Rs. 11,197 Million Revenue and Rs. 1,140 Million Operational PAT
AI Summary
Strides Pharma Science Ltd has announced its consolidated financial results for the quarter ended June 30, 2025, reporting a revenue of Rs. 11,197 million, a 6.2% year-over-year growth. The EBITDA grew 14.8% YoY to Rs. 2,181 million, with an EBITDA margin at 19.5%. Operational PAT grew 80.6% YoY to Rs. 1,140 million, resulting in an operational EPS of 12.4. The company's focus on cost management and diligent execution has contributed to this robust performance.
Key Highlights
- Revenue at Rs. 11,197 million, grew 6.2% YoY
- EBITDA grew 14.8% YoY to Rs. 2,181 million with EBITDA margin at 19.5%
- Operational PAT at Rs. 1,140 million, grew 80.6% YoY
- Operational EPS at 12.4
- ROCE stands at 15.1% for Q1